This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Brian Vastag

JAMA. 2003;289:290.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

At a December press briefing, the Food and Drug Administration (FDA) announced the seizure of 3000 bottles of EverCLR, a dietary supplement marketed by Halo Supply Company of San Diego, Calif, in what the agency called an "example of its commitment to strong enforcement . . . of unapproved drug claims." The product was sold as a treatment for herpesvirus and protection from colds and influenza.

The move comes shortly after the US Court of Appeals for the District of Columbia Circuit restricted the FDA's authority to regulate dietary supplement claims. Observers said the raid was an attempt to send a clear signal about the types of claims that remain off-limits.

In the EverCLR case, the FDA charged the company with selling an "unapproved and therefore illegal new drug" because the product was marketed to treat specific diseases or conditions. Concurrent with the seizure, the agency released a . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?